Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer
Rupert Bartsch(Universitätszahnklinik Wien), Guenther G. Steger(Mount Vernon Hospital), Florian Fitzal, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Anna S. Berghoff(Medical University of Vienna), Catharina DeVries(Comprehensive Cancer Center Vienna), Margaretha Rudas(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Christoph Zielinski(Vienna General Hospital), Ursula Pluschnig(Medical University of Vienna), Andrea Rottenfusser(Comprehensive Cancer Center Vienna), Robert M. Mader(Centre de Recherche en Économie et Management), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 52
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k